Chemistry:JNJ-7777120
From HandWiki
Short description: Chemical compound
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H16ClN3O |
| Molar mass | 277.75 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
JNJ-7777120 was a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H4 receptor.[1] It has anti-inflammatory effects,[2] and has been demonstrated to be superior to traditional (H1) antihistamines in the treatment of pruritus (itching).[3] The drug was abandoned because of its short in vivo half-life and hypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clinical studies.[4]
See also
References
- ↑ "Cloning and pharmacological characterization of the dog histamine H(4) receptor". Eur. J. Pharmacol. 592 (1–3): 26–32. July 2008. doi:10.1016/j.ejphar.2008.06.095. PMID 18639542.
- ↑ "A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties". Journal of Pharmacology and Experimental Therapeutics 309 (1): 404–13. Apr 2004. doi:10.1124/jpet.103.061754. PMID 14722321.
- ↑ "Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus". Journal of Allergy and Clinical Immunology 119 (1): 176–83. Jan 2007. doi:10.1016/j.jaci.2006.08.034. PMID 17208599.
- ↑ "Clinical Development of Histamine H4 Receptor Antagonists". Histamine and Histamine Receptors in Health and Disease. Handbook of Experimental Pharmacology. 241. 2017. pp. 301–320. doi:10.1007/164_2016_130. ISBN 978-3-319-58192-7.
 |  |
